CLINICAL TRIALS PROFILE FOR FLECAINIDE ACETATE
✉ Email this page to a colleague
All Clinical Trials for FLECAINIDE ACETATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002996 ↗ | Flecainide in Treating Patients With Chronic Neuropathic Pain | Completed | National Cancer Institute (NCI) | Phase 2 | 1998-02-01 | RATIONALE: Flecainide therapy may help patients with neuropathic pain live more comfortably. PURPOSE: Phase II trial to study the effectiveness of flecainide in treating patients with chronic neuropathic pain from cancer or AIDS. |
| NCT00002996 ↗ | Flecainide in Treating Patients With Chronic Neuropathic Pain | Completed | Eastern Cooperative Oncology Group | Phase 2 | 1998-02-01 | RATIONALE: Flecainide therapy may help patients with neuropathic pain live more comfortably. PURPOSE: Phase II trial to study the effectiveness of flecainide in treating patients with chronic neuropathic pain from cancer or AIDS. |
| NCT00189319 ↗ | To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation | Completed | MEDA Pharma GmbH & Co. KG | Phase 4 | 2003-09-01 | The purpose of this study is to evaluate the management of paroxysmal atrial fibrillation with controlled release flecainide on patient's quality of life. |
| NCT01117454 ↗ | Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia | Completed | Vanderbilt University | N/A | 2011-12-01 | The purpose of this study is to test whether the addition of oral flecainide to standard therapy will reduce ventricular ectopy on exercise test compared to placebo plus standard therapy in patients with Catecholaminergic Polymorphic Ventricular Tachycardia. |
| NCT01117454 ↗ | Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia | Completed | Vanderbilt University Medical Center | N/A | 2011-12-01 | The purpose of this study is to test whether the addition of oral flecainide to standard therapy will reduce ventricular ectopy on exercise test compared to placebo plus standard therapy in patients with Catecholaminergic Polymorphic Ventricular Tachycardia. |
| NCT03539302 ↗ | INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT) | Recruiting | InCarda Therapeutics Australia Pty Ltd. | Phase 2 | 2018-05-29 | The study consists of 3 parts (Part A, Part B and Part C). Part A was an open-label, randomized, multi center design to evaluate the feasibility of administration of inhaled flecainide in two dosing regimens. Part B was an open-label, multicenter design to confirm the safety (including tolerability) and efficacy of the optimal inhaled flecainide dose determined from Part A. Part C is currently ongoing and is an open-label, multi center study with exploratory objectives to explore the feasibility of patient-led self administration of flecainide. Part C also includes an exploratory sub-study to assess the feasibility of implementing a portable cardiac ultrasound (HHE) at screening in an emergent setting. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FLECAINIDE ACETATE
Condition Name
Clinical Trial Locations for FLECAINIDE ACETATE
Trials by Country
Clinical Trial Progress for FLECAINIDE ACETATE
Clinical Trial Phase
Clinical Trial Sponsors for FLECAINIDE ACETATE
Sponsor Name
